Abbott Laboratories announced that it has set aside $1.5 billion dollars for a potential off-label marketing settlement with the U.S. Justice Department. If the settlement goes through, it will be the second largest off-label settlement in history, eclipsed only by Pfizer’s $2.3 billion deal in 2009. Whistleblower lawsuits allege that Abbott marketed Depakote, its epilepsy drug, for various other unapproved uses including autism, sexual compulsions and aggressive dementia patients. The unapproved uses were promoted in a number of U.S. long-term care and assisted-living facilities.
Full story here: http://bit.ly/sdrVGg